Abstract
This article highlights the author's experiences as a patient advocate serving on the Food and Drug Administration (FDA) Biological Response Modifiers Committee. It provides an overview of the National Organization for Rare Disorders and the scope of the orphan disease problem. The author explains the process of serving on an advisory committee, and highlights the important role of patient advocates in protecting the patient's best interests.
Get full access to this article
View all access options for this article.
